In 2023, an inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer was referred to the Senate Community Affairs References Committee. Australian Genomics collaborated with the Australian Alliance for Indigenous Genomics (ALIGN) to prepare a joint response that highlighted the health inequities experienced by Indigenous Australians in the context of rare and less common cancers, and the lack of reimbursement for comprehensive genomic profiling amongst other issues, with several key recommendations to improve equity of outcomes.
